The findings, which appear in the November 29, 2013 issue of the journalScience, focus on a protein known as E2 envelope glycoprotein.
A team of Massachusetts General Hospital (MGH) investigators working to create “protocells” — primitive synthetic cells consisting of a nucleic acid strand encased within a membrane-bound compartment — have accomplished an important step towards their goal. In the November 28 issue of Science, the investigators describe
The European Commission recently granted Wageningen University and partners a 11 million euro international research project focusing on preventing and remediating soil degradation in Europe. The RECARE project is a joint initiative of 27 institutions and organizations in Europe. Wageningen University is lead contractor, with a.o. Alterra and ISRIC as partners.
Monoclonal antibody therapy is the use of monoclonal antibodies (or mAb) to specifically target cells.
The main objective is stimulating the patient’s immune system to attack the malignant tumor cells and the prevention of tumor growth by blocking specific cell receptors.
A study led by researchers at Boston University School of Medicine (BUSM) demonstrates a new mechanism involving a signaling protein and its receptor that may block the formation of new blood vessels and cancer growth. The findings are published in the December issue of Science Signaling.